Optimizing PARP Inhibitors Through Applying Evolving Technology and Clinical Evidence for Markers of Homologous Recombination Repair

Christine M. Walko, PharmD, FCCP, BCOP graduated with her PharmD degree from Duquesne University in Pittsburgh, Pennsylvania, and completed a pharmacy practice residency at the Medical College of Virginia/VCU in Richmond, Virginia, and a hematology/oncology specialty residency at the University of North Carolina (UNC). She stayed at UNC to complete a 2-year academic oncology fellowship focused on drug metabolism and translational research before taking an Assistant Professor position at UNC in the Division of Pharmacotherapy and Experimental Therapeutics until being recruited to Moffitt Cancer Center in January 2014 to assist with starting the institution’s first Precision Medicine Program. Dr. Walko is now a Senior Member in the Department of Pathology at Moffitt Cancer Center, Program Leader for Precision Medicine and an Attending on the Precision Medicine Clinical Service. She is also a Co-Chair for the ASCO TAPUR trial Molecular Tumor Board (MTB) and variant expert for the nationwide SWOG Precision Medicine trial focused on the clinical utility of Molecular Tumor Boards in Community Oncology Practices. Her research focus is on optimizing drug therapy using pharmacogenomics and pharmacokinetics to personalize intravenous and oral anticancer therapy for patients with cancer.

Jeannie Chern, MD, ScM is an Associate Member in Gynecologic Oncology at Moffitt Cancer Center. She completed Residency in Obstetrics and Gynecology at the University of South Florida and Gynecologic Oncology Fellowship at New York University. She is the lead for genetics education and tumor board. In addition, she is the assistant program director for the GYN oncology fellowship. Her clinical focus is personalization and comprehensive care for women with gynecologic cancers, with a special interest in the surgical management of advanced malignancies. Dr. Chern’s research is involved in understanding genetic factors associated with gynecologic malignancies to improve and guide patient care.

Relevant Financial Relationship Disclosures

The following persons in control of this activity’s content have relevant financial relationships:

• Jeannie Chern: AstraZeneca - Consultant, Advisor, and Speaker’s bureau; Baxter – Consultant; Equinox – Consultant; GSK - Advisory Board; Zentalis - Principal Investigator

All other persons in control of content do not have any relevant financial relationships with an ineligible company. As defined by the Standards of Integrity and Independence in Accredited Education definition of ineligible company. All relevant financial relationships have been mitigated prior to the CE activity.

Resources

• Optimizing PARP Inhibitor Outcomes in Cancer Therapy: Focus on Biomarkers of Homologous Recombination Repair